[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201990071A1 - Композиция пептидной вакцины - Google Patents

Композиция пептидной вакцины

Info

Publication number
EA201990071A1
EA201990071A1 EA201990071A EA201990071A EA201990071A1 EA 201990071 A1 EA201990071 A1 EA 201990071A1 EA 201990071 A EA201990071 A EA 201990071A EA 201990071 A EA201990071 A EA 201990071A EA 201990071 A1 EA201990071 A1 EA 201990071A1
Authority
EA
Eurasian Patent Office
Prior art keywords
vaccine composition
peptide vaccine
pharmaceutical composition
relates
composition
Prior art date
Application number
EA201990071A
Other languages
English (en)
Inventor
Гвенн Эвелин Мюлдер
Original Assignee
АйЭсЭй ФАРМАСЬЮТИКАЛЗ Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by АйЭсЭй ФАРМАСЬЮТИКАЛЗ Б.В. filed Critical АйЭсЭй ФАРМАСЬЮТИКАЛЗ Б.В.
Publication of EA201990071A1 publication Critical patent/EA201990071A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001114—CD74, Ii, MHC class II invariant chain or MHC class II gamma chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

Изобретение относится к новой восстанавливающей композиции, к фармацевтической композиции и набору из частей, включающему указанную восстанавливающую композицию. Изобретение также относится к способу лечения с использованием указанной фармацевтической композиции и/или к фармацевтической композиции для применения в качестве лекарственного средства. Также изобретение относится к способу восстановления высушенных пептидов и способу получения фармацевтической композиции с использованием восстанавливающей композиции по изобретению.
EA201990071A 2016-06-20 2017-06-19 Композиция пептидной вакцины EA201990071A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16175215 2016-06-20
PCT/EP2017/064882 WO2017220463A1 (en) 2016-06-20 2017-06-19 Formulation of a peptide vaccine

Publications (1)

Publication Number Publication Date
EA201990071A1 true EA201990071A1 (ru) 2019-06-28

Family

ID=56148213

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990071A EA201990071A1 (ru) 2016-06-20 2017-06-19 Композиция пептидной вакцины

Country Status (14)

Country Link
US (3) US10702598B2 (ru)
EP (2) EP3471758A1 (ru)
JP (3) JP7115803B2 (ru)
KR (2) KR20190020098A (ru)
CN (2) CN117018170A (ru)
AU (2) AU2017281389B2 (ru)
CA (1) CA3027459A1 (ru)
EA (1) EA201990071A1 (ru)
IL (2) IL291537B2 (ru)
MX (2) MX2018015749A (ru)
MY (1) MY189551A (ru)
SG (1) SG11201811442UA (ru)
WO (1) WO2017220463A1 (ru)
ZA (2) ZA201900367B (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2953446A1 (en) 2014-06-26 2015-12-30 The Rockefeller University Acinetobacter lysins
US20180072990A1 (en) * 2015-03-20 2018-03-15 Children's National Medical Center Generating virus or other antigen-specific t cells from a naïve t cell population
CA3027459A1 (en) * 2016-06-20 2017-12-28 Isa Pharmaceuticals B.V. Formulation of a peptide vaccine
CA3062591A1 (en) 2017-05-08 2018-11-15 Gritstone Oncology, Inc. Alphavirus neoantigen vectors
CA3088837A1 (en) * 2018-01-24 2019-08-01 The Council Of The Queensland Institute Of Medical Research Hpv immunotherapy
WO2019226941A1 (en) * 2018-05-23 2019-11-28 Gritstone Oncology, Inc. Shared antigens
CN114072516B (zh) 2019-05-30 2025-01-14 磨石生物公司 经修饰的腺病毒
CA3148132A1 (en) * 2019-08-15 2021-02-18 Isam KHALAILA Delivery peptides and methods of using the same
US20230248814A1 (en) * 2020-06-01 2023-08-10 The Broad Institute, Inc. Compositions and methods for treating merkel cell carcinoma (mcc) using hla class i specific epitopes
EP4192496A4 (en) 2020-08-06 2025-01-01 Gritstone Bio Inc MULTIPLE EPITOPE VACCINE CASSETTES
CN117730247A (zh) 2021-07-12 2024-03-19 Isa制药有限公司 复杂混合物中改善的物质定量
CN113842455B (zh) * 2021-08-27 2022-05-13 北京康乐卫士生物技术股份有限公司 一种新型冠状病毒疫苗的佐剂及其应用和新型冠状病毒二价重组疫苗
KR102545000B1 (ko) * 2021-10-20 2023-06-16 전옥님 그래핀을 이용한 전자파 차폐 시트
EP4471055A1 (en) * 2022-01-25 2024-12-04 Xiamen University Epitope peptide and antibody for treating hbv infection and related diseases
WO2024068636A1 (en) 2022-09-27 2024-04-04 Isa Pharmaceuticals B.V. Adjuvanted immunogenic peptides for intradermal administration
WO2024149888A1 (en) 2023-01-12 2024-07-18 Isa Pharmaceuticals B.V. Improved lipopeptide quantification
WO2024223299A2 (en) 2023-04-26 2024-10-31 Isa Pharmaceuticals B.V. Methods of treating cancer by administering immunogenic compositions and a pd-1 inhibitor
WO2025008085A1 (en) * 2023-07-05 2025-01-09 Isa Pharmaceuticals B.V. Immunotherapy for the treatment of prame-expressing cancers

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ42894A3 (en) 1991-08-26 1995-02-15 Scripps Research Inst Peptides inducing cytotoxic response of t lymphocytes to hepatitis b virus
US20110097352A9 (en) 1992-01-29 2011-04-28 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
US7611713B2 (en) 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
PT726758E (pt) 1993-08-02 2003-03-31 Scripps Research Inst Peptidos para induzir respostas de linfocitos t citotoxicos ao virus da hepatite b
ES2330017T3 (es) 1998-05-23 2009-12-03 Leiden University Medical Center Ligandos de cd40 y peptidos de ctl para tratar tumores.
US20030118588A1 (en) 1999-05-22 2003-06-26 Linda Diehl Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40
FR2794370B1 (fr) 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
DE10059631A1 (de) 2000-12-01 2002-07-18 Medigene Ag T-Zellepitope des Papillomavirus L1-und E7-Proteins und ihre Verwendung in Diagnostik und Therapie
EP2363406B1 (en) * 2000-12-08 2019-02-27 Academisch Ziekenhuis Leiden Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses
US7202034B2 (en) * 2000-12-08 2007-04-10 Academisch Ziekenhuis Leiden Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses
FR2824326B1 (fr) 2001-05-04 2004-03-19 Commissariat Energie Atomique Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications
EP1479761A1 (en) 2003-05-21 2004-11-24 PrimaGen Holding B.V. New enterovirus, vaccines, medicaments and diagnostic kits
SI1687019T1 (en) * 2003-11-20 2018-04-30 Novo Nordisk A/S Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
GB0417430D0 (en) 2004-08-05 2004-09-08 Uc3 A novel HPV vaccine comprising peptides from host cell proteins
EP1904052A4 (en) * 2005-06-17 2008-12-10 Hospira Australia Pty Ltd LIQUID PHARMACEUTICAL COMPOSITIONS OF DOCATEXEL
CA2996732C (en) 2007-03-26 2020-10-27 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Prame derived peptides and immunogenic compositions comprising these
EP2155780B1 (en) 2007-05-31 2013-02-27 Academisch Ziekenhuis Leiden h.o.d.n. LUMC P53 peptide vaccine
MX2009012922A (es) 2007-05-31 2010-07-05 Academisch Ziekenhuis Leiden H Vacunacion intradermica de un peptido del virus del papiloma humano.
CN105031610B (zh) 2007-05-31 2020-06-19 莱顿教学医院 侵润宫颈恶性肿瘤的t细胞所靶向的用于疫苗的hpv表位
KR20090125629A (ko) 2008-06-02 2009-12-07 바이오코아 주식회사 면역성 펩타이드 및 그 펩타이드를 포함하는 ｈｐｖ 관련질환 예방 또는 치료용 조성물
KR20090125628A (ko) 2008-06-02 2009-12-07 바이오코아 주식회사 면역성 펩타이드 및 그 펩타이드를 포함하는 ｈｐｖ 관련질환 예방 또는 치료용 조성물
JP5797190B2 (ja) 2009-05-15 2015-10-21 アイ アール エックス セーラピューティクス， インコーポレイテッド ワクチン免疫療法
US8697644B2 (en) 2011-03-10 2014-04-15 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of peptide drugs
WO2013006050A1 (en) 2011-07-06 2013-01-10 Isa Pharmaceuticals B.V. Peptides inducing or enhancing an immune response against prostate-specific membrane protein (PSMA)
NL2007536C2 (en) 2011-10-05 2013-04-08 Academisch Ziekenhuis Leiden Lumc Adjuvant compound.
WO2013113326A1 (en) * 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
AU2013273482A1 (en) * 2012-06-06 2014-12-11 Bionor Immuno As Peptides derived from viral proteins for use as immunogens and dosage reactants
GB201223386D0 (en) 2012-12-24 2013-02-06 Immune Targeting Systems Its Ltd Vaccine
KR102341899B1 (ko) 2013-04-07 2021-12-21 더 브로드 인스티튜트, 인코퍼레이티드 개인맞춤화 신생물 백신을 위한 조성물 및 방법
JP6780852B2 (ja) 2014-06-02 2020-11-04 アイエスエー ファーマシューティカルズ ビー．ヴイ．ＩＳＡ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｂ．Ｖ． Ｂ型肝炎ウイルス感染に対する治療ワクチン接種のための合成長鎖ペプチド（ｓｌｐ）
CA3027459A1 (en) * 2016-06-20 2017-12-28 Isa Pharmaceuticals B.V. Formulation of a peptide vaccine

Also Published As

Publication number Publication date
KR20230030032A (ko) 2023-03-03
EP3552623A1 (en) 2019-10-16
JP7115803B2 (ja) 2022-08-09
CN117018170A (zh) 2023-11-10
US12097252B2 (en) 2024-09-24
ZA202100578B (en) 2023-03-29
JP2022141878A (ja) 2022-09-29
CN109641039A (zh) 2019-04-16
MX2018015749A (es) 2019-06-17
US20190231863A1 (en) 2019-08-01
SG11201811442UA (en) 2019-01-30
AU2017281389B2 (en) 2024-02-22
JP2024069303A (ja) 2024-05-21
US20200297835A1 (en) 2020-09-24
MY189551A (en) 2022-02-16
IL263846B (en) 2022-04-01
IL291537B2 (en) 2023-11-01
CN109641039B (zh) 2023-08-04
AU2017281389A1 (en) 2019-02-07
IL291537A (en) 2022-05-01
IL263846A (en) 2019-01-31
JP2019525950A (ja) 2019-09-12
ZA201900367B (en) 2024-07-31
US10702598B2 (en) 2020-07-07
EP3471758A1 (en) 2019-04-24
IL291537B1 (en) 2023-07-01
CA3027459A1 (en) 2017-12-28
MX2023003875A (es) 2023-04-18
KR20190020098A (ko) 2019-02-27
AU2024202005A1 (en) 2024-04-18
US11426458B2 (en) 2022-08-30
US20230233658A1 (en) 2023-07-27
WO2017220463A1 (en) 2017-12-28

Similar Documents

Publication Publication Date Title
EA201990071A1 (ru) Композиция пептидной вакцины
UA124347C2 (uk) Циклічна динуклеотидна сполука
EA201891186A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
EA201790630A1 (ru) Способы получения рибозидов
EA201790413A1 (ru) Антитела против tigit
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201891399A1 (ru) Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний
EA201591839A1 (ru) Терапевтические пептиды
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
MX2017009595A (es) Compuestos antisenescentes y usos de los mismos.
EA201791249A1 (ru) Получаемые из cd44v6 циклические пептиды для лечения злокачественных опухолей и связанных с ангиогенезом заболеваний
EA201791537A1 (ru) Фармацевтическая композиция на основе наночастиц доцетаксела-альбумина, способ ее получения и ее применение
EA201891342A1 (ru) Изоиндольные соединения
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
EA202090164A1 (ru) Изотретиноиновые перорально-слизистые композиции и способы их применения
WO2015043566A8 (de) Zyklische, amyloid-beta-bindende peptide und deren verwendung
EA201690966A1 (ru) Новое соединение для лечения тяжелой гипогликемии
MD20180049A2 (ru) Фармацевтическая композиция
EA201790771A1 (ru) Фармацевтические композиции длительного действия для лечения гепатита c
EA201790776A1 (ru) Комбинированные композиции длительного действия и способы лечения гепатита с
EA201700254A1 (ru) Комбинация
EA201890209A1 (ru) Композиция, содержащая танины